NatureCell is a biotechnology company focused on regenerative medicine, stem cell therapeutics, and bio-based consumer products. Its primary business segment involves the research, development, and commercialization of autologous adipose-derived stem cell therapies, most notably JointStem for osteoarthritis, which has received RMAT and Breakthrough Therapy designations from the US FDA. The company also develops Vascostem for severe peripheral arterial disease and Buerger's disease, and AstroStem for Alzheimer's disease. Through its subsidiary Nature Cell America Inc., NatureCell conducts US clinical trials for stem cell therapies targeting autism spectrum disorder and critical limb ischemia. The company manufactures and sells stem cell culture media, a key raw material for cell therapy production, and operates a cosmetics division under the Dr.Jucre brand, which utilizes stem cell culture medium as a primary ingredient in skincare products. Additionally, NatureCell produces vegan health beverages, including barley sikhye and fermented red ginseng drinks, sold through domestic retail channels and OEM partnerships. The company is preparing to launch an amniotic stem cell storage service. NatureCell collaborates with Albio and BioStar Stem Cell Technology Research Institute for R&D and clinical development.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage naturecell.co.kr
Sector Healthcare IR page —
Tags
stem cell therapy, regenerative medicine, osteoarthritis, autism spectrum disorder, cell culture media, cosmeceuticals, health beverages, autologous stem cells, clinical trials, biopharmaceuticals, JointStem, Vascostem, AstroStem, Dr.Jucre, Nature Cell America Inc., Albio, BioStar Stem Cell Technology Research Institute, NatureCell Members, BioStar Shop, Sikhye, Fermented Red Ginseng K, Graviola K
Press page —

Metrics

Valuation  
Market cap ₩ 1.153T
Market cap (USD) $ 848.399M
P/E -425.55
PEG —
P/BV 18.31
P/S 56.21
P/OCF -169.42
P/FCF -51.31
Dividend yield —
Turnover / mcap —
Returns  
ROE -4.4%
ROI -4.5%
ROIC -4.3%
Profit margin -13.7%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -76.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 20.735B 32.334B 19.351B 21.252B 20.354B 16.72B 23.072B 26.715B 27.215B 26.788B 30.554B 25.355B 29.208B
Net profit -2.838B 1.226B -11.68B -6.814B -32.031B -18.87B 902.009M 2.235B -460.739M -3.223B -1.335B 1.895B -3.509B
Free cash flow -16.386B -1.59B — -18.659B — — — — — -4.141B -275.928M -184.011M 424.974M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 22K — — — — — — — — — — — —
P/FCF -86.51 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 4.37B 4.1B 3.69B 3.56B 5.1B 7.07B 8.75B 3.95B 9.82B 4.99B
↳ YoY growth -7.3% -6.1% -10.1% -3.5% +43.6% +38.5% +23.8% -54.8% +148.5% -49.2%
↳ 5y CAGR -1.1% -0.9% +1.6% +10.1% +16.4% +1.4% +22.5% -0.5%
Other receivables (KRW) 3.19B 551M 414M 2.97B 2.44B 2.86B 12.8B 518M — —
Borrowings, current (KRW) 46M 2.24B 2.24B 2.24B 11.5B 0.00 24.3B — — —
Borrowings, non-current (KRW) 1.92B 1.87B 69M 23M — — 0.00 — — —
Bonds payable (KRW) 4.32B 0.00 0.00 — 7.35B 0.00 24.3B — — —
Lease liabilities (KRW) — — 0.00 2.32B 2.7B 2.54B 1.21B 2.31B 1.78B 2.8B
Cash and deposits (KRW) 3.45B 9.04B 14.9B 21.2B 41.5B 32.6B 31.3B 29.9B 28.4B 16.8B
Intangible assets (KRW) 5.1B 2.81B 2.63B 3.43B 3.24B 3.12B 2.87B 2.69B 2.51B 2.36B
Right-of-use assets (KRW) — — 0.00 2.33B 2.66B 2.46B 1.03B 2.28B 1.8B 2.32B
Net debt (borrowings + leases - cash) (KRW) -1.48B -4.93B -12.6B -16.6B -27.3B -30B -5.72B — — —
Cash flow detail
Operating cash flow (KRW) -2.14B 3.48B 3.7B 358M -5.41B -10.1B -14.9B -2.13B 1.51B 157M
Purchases of property, plant and equipment (KRW) -2B — — — — — -3.79B -6.12B -3.1B -16.5B
Purchases of intangible assets (KRW) -4.53B — — — — — -1.86M -676,800 -17.9M -47.5M
Change in receivables (cash effect) (KRW) -2.99B 2.64B 910M -2.54B -1.3B -2.37B -4.2B 8.22B — —
Change in inventories (cash effect) (KRW) -1.59B 1.16B 1.56B 63.3M -754M -407M -887M -210M — —
Change in payables (cash effect) (KRW) 287M -1.48B -2.49M 371M -395M 1.27B 107M -1.07B — —
Interest paid (cash effect) (KRW) -266M -322M -170M -169M -113M -66M -159M -598M -161M -194M
Income taxes paid (cash effect) (KRW) 48.3M 9.53M 29.9M 65M 5.46M — — -137M 26.5M 37.9M
Share-based compensation (KRW) 1.98B 1.81B 13.4M 9.16M — — — — — —
Operating cash flow before change in receivables (KRW) -645M 837M 2.79B 2.9B -4.11B -7.78B -10.7B -10.4B — —
Free cash flow (OCF - PPE - intangibles) (KRW) -8.67B — — — — — -18.7B -8.25B -1.61B -16.4B
Income detail
Total comprehensive income (KRW) -2.86B -565M 3.19B 841M -19.2B -31.5B -8.33B -12.5B 1.28B -3.04B
Comprehensive income to owners (KRW) — — — — — -31.5B -8.33B -12.5B 1.28B -3.04B
Provision for credit losses (KRW) -44.2M 42.8M 267M -77.6M 2.01B -1.03B -802M -60.1M — —
Credit cost ratio (credit losses / average receivables) (%) 0.7% 0.7% 6.1% 1.5% 28.5% 11.8% 5.1% 0.5% — —
Reported Apr 1, 2019 Apr 1, 2019 May 15, 2019 May 15, 2020 Mar 19, 2021 Mar 21, 2024 Mar 19, 2025 Mar 19, 2025 Mar 19, 2025 Mar 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

분기보고서 (2026.09) Bull 0 Bear 4 Results
전환가액의조정 Bull 0 Bear 4 Financing
주요사항보고서(유형자산양수결정) Bull 3 Bear 0 Order/contract

Prompts

NATURECELL (ticker 007390), listed in South Korea.

ETFs Holding NATURECELL

ETF Weight in ETF Shares Market value As of
AVEE 0.02% 1,604 $ 25.984K Nov 16, 2026
AVXC 0.00% 32 $ 518.39 Nov 16, 2026